Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia

Texto completo
Autor(es):
Correia, Banny Silva Barbosa [1] ; Nani, Joao Victor [2, 3] ; Waladares Ricardo, Raniery [1] ; Stanisic, Danijela [1] ; Costa, Tassia Brena Barroso Carneiro [1] ; Hayashi, Mirian A. F. [2, 3] ; Tasic, Ljubica [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas UNICAMP, Inst Quim, BR-13083970 Campinas - Brazil
[2] Univ Fed Sao Paulo UNIFESP, Escola Paulista Med EPM, Dept Farmacol, BR-04044020 Sao Paulo - Brazil
[3] Univ Sao Paulo FMRP USP, Fac Med Ribeirao Preto, Natl Inst Translat Med INCT TM, CNPq, BR-14049900 Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: BIOMEDICINES; v. 9, n. 3 MAR 2021.
Citações Web of Science: 0
Resumo

Schizophrenia (SCZ) treatment is essentially limited to the use of typical or atypical antipsychotic drugs, which suppress the main symptoms of this mental disorder. Metabolic syndrome is often reported in patients with SCZ under long-term drug treatment, but little is known about the alteration of lipid metabolism induced by antipsychotic use. In this study, we evaluated the blood serum lipids of a validated animal model for SCZ (Spontaneously Hypertensive Rat, SHR), and a normal control rat strain (Normotensive Wistar Rat, NWR), after long-term treatment (30 days) with typical haloperidol (HAL) or atypical clozapine (CLZ) antipsychotics. Moreover, psychostimulants, amphetamine (AMPH) or lisdexamfetamine (LSDX), were administered to NWR animals aiming to mimic the human first episode of psychosis, and the effects on serum lipids were also evaluated. Discrepancies in lipids between SHR and NWR animals, which included increased total lipids and decreased phospholipids in SHR compared with NWR, were similar to the differences previously reported for SCZ patients relative to healthy controls. Administration of psychostimulants in NWR decreased omega-3, which was also decreased in the first episode of psychosis of SCZ. Moreover, choline glycerophospholipids allowed us to distinguish the effects of CLZ in SHR. Thus, changes in the lipid metabolism in SHR seem to be reversed by the long-term treatment with the atypical antipsychotic CLZ, which was under the same condition described to reverse the SCZ-like endophenotypes of this validated animal model for SCZ. These data open new insights for understanding the potential influence of the treatment with typical or atypical antipsychotics on circulating lipids. This may represent an outcome effect from metabolic pathways that regulate lipids synthesis and breakdown, which may be reflecting a cell lipids dysfunction in SCZ. (AU)

Processo FAPESP: 19/09207-3 - Estudo do(s) mecanismo(s) molecular(es) e celular(es) em transtornos mentais
Beneficiário:João Victor Silva Nani
Modalidade de apoio: Bolsas no Brasil - Doutorado
Processo FAPESP: 14/50867-3 - INCT 2014: Instituto Nacional de Ciência e Tecnologia de Bioanalítica
Beneficiário:Lauro Tatsuo Kubota
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 21/01051-4 - Efeitos de psicoestimulantes e antipsicóticos na lipidômica do soro em um modelo animal para esquizofrenia
Beneficiário:Ljubica Tasic
Modalidade de apoio: Auxílio à Pesquisa - Publicações científicas - Artigo
Processo FAPESP: 18/24069-3 - Do biomonitoramento ao reconhecimento de assinaturas do exposoma humano visando antecipar riscos para uma saúde contínua
Beneficiário:Fernando Barbosa Júnior
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 19/13112-8 - Estudo dos mecanismos moleculares e celulares em transtornos mentais: estudos clínicos e modelos animais
Beneficiário:Mirian Akemi Furuie Hayashi
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 17/02413-1 - Validação da crotamina como biomarcador e avaliação do seu potencial uso na terapia de doenças humanas
Beneficiário:Mirian Akemi Furuie Hayashi
Modalidade de apoio: Auxílio à Pesquisa - Regular